OmniAb (OABI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
The annual meeting is scheduled for June 17, 2026, at the corporate headquarters, with shareholders of record as of April 23, 2026, eligible to vote on key proposals.
The agenda includes electing two Class I directors and ratifying the appointment of Ernst & Young LLP as the independent auditor for 2026.
Proxy materials are primarily distributed electronically to reduce costs and environmental impact, with paper copies available upon request.
Voting matters and shareholder proposals
Shareholders will vote on the election of Matthew W. Foehr and Jennifer Cochran, Ph.D., as Class I directors for terms expiring in 2029.
Ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, is on the agenda.
Shareholder proposals for the 2027 annual meeting must be received by January 5, 2027, to be included in the proxy statement.
Board of directors and corporate governance
The board consists of seven directors, with all but the CEO considered independent under Nasdaq rules.
Board leadership is separated between the chair and CEO roles to ensure independent oversight.
Four standing committees exist: Audit, Human Capital Management and Compensation (HCMC), Nominating and Corporate Governance, and Science and Technology, each with independent members and written charters.
Directors are selected based on integrity, experience, and diversity of perspectives; the board includes two female and five male directors.
Stock ownership guidelines and a Code of Business Conduct and Ethics are in place for directors and employees.
Latest events from OmniAb
- Q1 2026 revenue soared 247% to $14.4M, net loss narrowed, and guidance was raised.OABI
Q1 20268 May 2026 - Shareholders will vote on two directors and auditor ratification at the June 2026 meeting.OABI
Proxy filing29 Apr 2026 - Over 400 active programs and new technology launches drive growth and future cash flow.OABI
Corporate presentation24 Mar 2026 - 107 partners, 407 programs, new platforms, and 2026 revenue growth expected.OABI
Q4 20254 Mar 2026 - Q2 revenue up 10% to $7.6M, net loss narrowed, and partnerships and cash remain strong.OABI
Q2 20242 Feb 2026 - Expanding partnerships and innovative antibody platforms drive growth and long-term royalties.OABI
Jefferies Global Healthcare Conference31 Jan 2026 - Q3 revenue fell to $4.2M, but partner and program growth and $59.4M cash support future progress.OABI
Q3 202414 Jan 2026 - Double-digit partner and program growth, Q4 revenue up, 2025 revenue seen at $20–$25M.OABI
Q4 202424 Dec 2025 - Resale registration covers 21.25M shares from a $30M private placement; no proceeds to company.OABI
Registration Filing16 Dec 2025